CONCORD, Calif.--(BUSINESS WIRE)--May 16, 2007--Cerus Corporation (NASDAQ: CERS) announced today that Company management will present at the 6th Annual JMP Securities Research Conference. Cerus' presentation will begin at 5:30 p.m. EDT on Tuesday, May 22, 2007. To access the live webcast, please log on to the Company's website at www.cerus.com. An archived presentation will be available on the website until May 29, 2007.

ABOUT CERUS

Cerus Corporation is a biopharmaceutical company that develops and commercializes novel, proprietary products in the fields of blood safety and immunotherapy to provide safer, more effective medical options to patients in areas of substantial unmet medical needs. In the field of blood safety, the company is developing and commercializing the INTERCEPT Blood System, which is based on the company's proprietary Helinx technology. The system is designed to enhance the safety of donated blood components by inactivating viruses, bacteria, parasites and other pathogens, as well as potentially harmful white blood cells. In the field of immunotherapy, the company is employing its proprietary attenuated Listeria vaccine platform to develop a series of novel therapies to treat cancer, and it is applying its proprietary Killed But Metabolically Active technology platform in the research and development of prophylactic and therapeutic vaccines for infectious diseases.

INTERCEPT, INTERCEPT Blood System and Helinx are trademarks of Cerus Corporation.

CONTACT: Cerus Corporation
Myesha Edwards, 925-288-6017
Corporate Communications & Investor Relations

SOURCE: Cerus Corporation